Table 5.

Ongoing protocols of molecular targeted therapies as radiosensitizers

Phase 1

-Cetuximab, cisplatin, and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer (GOG-9918, NCT00104910)

-A phase I-II study of the COX-2 inhibitor celecoxib and chemoradiation in patients with locally advanced cervical cancer (RTOG C-0128)

Phase 2

-Radiation therapy plus celecoxib, fluorouracil, and cisplatin in patients with locally advanced cervical cancer. NCT00023660

-Phase II trial of the combination of DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor magnesium valproate added to cisplatin chemoradiation in FIGO stage IIIB patients [128, 129].